Biosimilars have finally hit the US market. Now comes the hard part.
The US Biosimilars market is open for business. What will it take to get customers in the door?
Get our new report, Biosimilars: US Payer Perspectives (2016).
Packed with candid observations from payers, the report explores how biosimilars manufacturers can win over payers and physicians—and get their fledgling commercial strategies off the ground.
Get the information you need to navigate a landscape marked by legal challenges, regulatory hold-ups, and debates over naming, extrapolation and interchangeability.
“Do we know they’re coming? Yes. Have we been anticipating it? Yes. Do we
know when more biosimilars will reach the US market? Not at the moment.”
FirstWord interviewed 10 expert payers from the US between January 27 and February 2, 2016. Respondents have between 5 and 30 years’ experience working in a variety of organisations, including:
All respondents met FirstWord’s stringent screening criteria, and were compensated for participating. To encourage frank and forthright responses, their names have been withheld.
Questions? Please contact us at info@fwreports.com.
Biosimilars have finally hit the US market. Now comes the hard part.
The US Biosimilars market is open for business. What will it take to get customers in the door?
Get our new report, Biosimilars: US Payer Perspectives (2016).
Packed with candid observations from payers, the report explores how biosimilars manufacturers can win over payers and physicians—and get their fledgling commercial strategies off the ground.
Get the information you need to navigate a landscape marked by legal challenges, regulatory hold-ups, and debates over naming, extrapolation and interchangeability.
“Do we know they’re coming? Yes. Have we been anticipating it? Yes. Do we
know when more biosimilars will reach the US market? Not at the moment.”
Pharmacy Director; Managed Care Organisation
FirstWord interviewed 10 expert payers from the US between January 27 and February 2, 2016. Respondents have between 5 and 30 years’ experience working in a variety of organisations, including:
All respondents met FirstWord’s stringent screening criteria, and were compensated for participating. To encourage frank and forthright responses, their names have been withheld.
All Contents Copyright © 2021 Doctor's Guide Publishing Limited All Rights Reserved